Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7771603 | 0.92 | ROCK2 (0.53) | SMYD3ROCK2ROCK1MAPK14CTDSP1 | |
| SCHEMBL7766531 | 0.88 | KMT2A (0.62) | RAB9A | |
| SCHEMBL1299449 | 0.87 | BRD4 (0.44) | SMYD3ROCK2ROCK1MAPK14CTDSP1 | |
| SCHEMBL1299448 | 0.87 | BRD4 (0.44) | SMYD3ROCK2ROCK1MAPK14CTDSP1 | |
| SCHEMBL1299766 | 0.87 | BRD4 (0.44) | SMYD3ROCK2ROCK1MAPK14CTDSP1 | |
| SCHEMBL8341550 | 0.85 | NAMPT (0.55) | MAPK14HPGDSMN1; SMN2 | |
| SCHEMBL20474743 | 0.84 | HDAC6 (0.56) | LMNANR1H4HPGD | |
| SCHEMBL184425 | 0.83 | NR1H4 (0.61) | NR1H4NPC1BRD4RAB9A | |
| SCHEMBL13999403 | 0.83 | ROCK2 (0.50) | ROCK2ROCK1LMNANR1H4NPC1 | |
| SCHEMBL1300236 | 0.83 | BRD4 (0.42) | NR1H4BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| EP-1758861-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005095343-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095343-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | SMYD3 4258/4885ROCK2 1702/4885ROCK1 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.